PureTech Health announced that the U.S. Food and Drug Administration and the European Commission have granted orphan drug designation to its deupirfenidone (LYT‑100) for the treatment of idiopathic pulmonary fibrosis (IPF). The designation applies to a rare disease affecting fewer than 200,000 people in the United States and fewer than 5 in 10,000 in the European Union.
Continue reading for full analysis...